To the Editor—Recent reports have linked retinal vascular diseases with the hypercoagulability and thromboembolic pathology of coronavirus disease 2019 (COVID-19). Central retinal artery occlusion (CRAO), also known as ocular stroke, is a sight-threatening ophthalmological emergency, and its reported correlation with COVID-19 is of particular interest to our territory-wide tertiary CRAO referral centre in Hong Kong.
In a literature search, we found only three case reports1 2 3 and two case series4 5 with at least one patient with COVID-19 presenting with stroke symptoms identified as CRAO. One case report on ophthalmic artery occlusion was excluded. Acharya et al1 reported a 60-year-old man with history of hypertension, hyperlipidaemia, coronary artery disease, and chronic obstructive pulmonary disease, who presented with right CRAO 12 days after testing positive for COVID-19. He had D-dimer level 42.131 (no unit provided), fibrinogen level [greater than]700 (no unit provided), and C-reactive protein (CRP) level 7.02 (no unit provided). Montesel et al2 reported a 59-year-old man with history of hypertension and hyperuricaemia who presented with left CRAO 69 days after testing positive for COVID-19. He had D-dimer level 2.059 ng/mL, fibrinogen level 5.9 g/L, and CRP level 184 mg/L. Murchison et al,3Sweid et al,4 and Alam et al,5 all affiliated with the same institution, apparently described the same patient, with similar lesion site and blood test results (some minor differences and/or errors in reporting notwithstanding). These authors all describe a 59-year-old man with history of hypertension who presented with right CRAO after testing positive for COVID-19 (date of positive test not reported). He had D-dimer level 450 ng/mL, fibrinogen level 5.45 g/L, and CRP level 21 mg/L.
Central retinal artery occlusion is a rare disease worldwide, with an estimated annual incidence of 0.85 per 100 000 population, which could account for the few published case reports. All cases had at least one known risk factor for CRAO, with hypertension being the commonest. The correlation of CRAO and COVID-19 is uncertain, but we believe these cases do not demonstrate any causal link.
Author contributions
SCL Au drafted the letter and all authors contributed to the critical revision of the letter for important intellectual content. All authors approved the final version for publication and take responsibility for its accuracy and integrity.
Conflicts of interest
All authors have disclosed no conflicts of interest.
Funding/support
This letter received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
1. Acharya S, Diamond M, Anwar S, Glaser A, Tyagi P. Unique case of central retinal artery occlusion secondary to COVID-19 disease. IDCases 2020;21:e00867.
2. Montesel A, Bucolo C, Mouvet V, Moret E, Eandi CM. Case report: central retinal artery occlusion in a COVID-19 patient. Front Pharmacol 2020;11:588384.
3. Murchison AP, Sweid A, Dharia R, et al. Monocular visual loss as the presenting symptom of COVID-19 infection. Clin Neurol Neurosurg 2020;201:106440.
4. Sweid A, Hammoud B, Weinberg JH, et al. Letter: thrombotic neurovascular disease in COVID-19 patients. Neurosurgery 2020;87:E400-6.
5. Alam S, Dharia RN, Miller E, Rincon F, Tzeng DL, Bell RD. Coronavirus positive patients presenting with stroke-like symptoms. J Stroke Cerebrovasc Dis 2021;30:105588.
Sunny CL Au; Callie KL Ko
Department of Ophthalmology, Pamela Youde Nethersole Eastern Hospital and Tung Wah Eastern Hospital, Hong Kong
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
In a literature search, we found only three case reports1 2 3 and two case series4 5 with at least one patient with COVID-19 presenting with stroke symptoms identified as CRAO. Acharya et al1 reported a 60-year-old man with history of hypertension, hyperlipidaemia, coronary artery disease, and chronic obstructive pulmonary disease, who presented with right CRAO 12 days after testing positive for COVID-19. Murchison et al,3Sweid et al,4 and Alam et al,5 all affiliated with the same institution, apparently described the same patient, with similar lesion site and blood test results (some minor differences and/or errors in reporting notwithstanding).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer